-
-
-
-
-
-
-
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
BioStem Technologies, Inc. (BSEM) Misses Q3 EPS by 23c
-
-
-
-
-
-
-
BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025
-
-
-
-
-
-
-
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million
-
-
-
-
-
-
-
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
-
-
-
-
-
-
-
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024
-
-
-
-
-
-
-
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft
-
1,211,629 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

